Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Researchers have discovered a key molecular "brake" — a protein called Id3 — that limits how well low-intensity pulsed ultrasound (LIPUS) heals bone defects. By developing a peptide that blocks Id3 and combining it with LIPUS, scientists significantly boosted bone regeneration in mice. The findings could pave the way for a non-invasive, drug-free approach to treating bone injuries.
Scientists at Capital Medical University in Beijing have uncovered a molecular pathway that explains — and could help optimize — how low-intensity pulsed ultrasound (LIPUS) promotes bone healing. The key player is a protein called Id3, which acts as a molecular "brake" that suppresses bone formation. When LIPUS is applied, it triggers a calcium-driven signaling cascade (Ca²⁺/CaN/NFATC3) that dials down Id3, freeing up a transcription factor called E2A to activate BMP4 signaling and, ultimately, new bone growth.
To put this insight to work, the team engineered a peptide called rID3 that directly blocks Id3's inhibitory function. When combined with LIPUS treatment in mice, rID3 significantly enhanced osteogenesis and improved healing of bone defects — all without the systemic side effects associated with drug-based therapies.
Key Takeaways:
Why it matters: Bone defects from trauma, surgery, or disease remain a major clinical challenge. A non-invasive, drug-free strategy combining ultrasound with a targeted peptide could offer a safer, more effective alternative to current treatments — though human trials are still needed.
